---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-023881"
form_type: "8-K"
ticker: "CRMD"
cik: "0001410098"
company_name: "CorMedix Inc."
filed_at: "2026-03-05T23:59:59+00:00"
generated_at: "2026-05-15T19:29:25.318065+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# CorMedix Q4 rev $128.6M; FY2025 net income $163M; reiterates 2026 guidance

## Summary
- Q4 net revenue $128.6M ($91.2M DefenCath, $37.4M Melinta); net income $14.0M vs $13.5M YoY.
- FY2025 total revenue $311.7M, pro forma $401.3M; net income $163.0M ($2.04 diluted EPS) vs prior year loss.
- Q4 adjusted EBITDA $77.2M; 2026 guidance: revenue $300-320M, adj. EBITDA $100-125M.
- Board approved $75M share repurchase program; cash and short-term investments $148.5M.
- Phase 3 Rezzayo ReSPECT data expected Q2 2026; TPN catheter lock study target completion H1 2027.

## SEC filing metadata
- accession: 0001213900-26-023881
- form_type: 8-K
- ticker: CRMD
- cik: 0001410098
- company_name: CorMedix Inc.
- filed_at: 2026-03-05T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1410098/000121390026023881/0001213900-26-023881-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1410098/000121390026023881/ea027968001-8k_cormedix.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-023881
- JSON: https://secwatch.observer/filing/0001213900-26-023881.json
- Plain text: https://secwatch.observer/filing/0001213900-26-023881.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.